HCK and acute myeloid leukemia: Taken together, these results provide strong support for the idea that Hck, Lyn and Fgr are viable inhibitor targets for AML therapy, and that selective inhibitors of these kinases may provide therapeutic benefit without the toxicity associated with broad-spectrum kinase inhibitors.